QUOTE AND NEWS
Forbes  Aug 29  Comment 
The U.S. federal government is spreading its support for Ebola virus treatments across developers of biological and small molecule therapeutics. BioCryst has received an additional $2.4 million to accelerate their broad-spectrum antiviral, BCX-4430.
StreetInsider.com  Aug 29  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/BioCryst+Pharma+%28BCRX%29+Receives+%242.4M+Contract+Modification+from+NIAID+for+BCX4430+Efficacy+Study/9792949.html for the full story.
Forbes  Aug 26  Comment 
Looking back to 90 days ago, BioCryst Pharmaceuticals, Inc. (NASD: BCRX) priced a $100,000,000 secondary stock offering at $10.00 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment...
StreetInsider.com  Aug 21  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/WHO+Offers+Update+on+Ebola+Outbreak+for+Aug.+17+-+18+%28TKMR%29+%28BCRX%29+%28NLNK%29/9773658.html for the full story.
StreetInsider.com  Aug 14  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/FDA+Warns+Against+Fake+Ebola+Treatment+Products+%28TKMR%29+%28BCRX%29+%28NLNK%29/9755592.html for the full story.
StreetInsider.com  Aug 13  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/BioCryst+Pharma+%28BCRX%29+Receives+Additional+Funding+from+NIAID+for+BCX4430/9747787.html for the full story.
Clusterstock  Aug 12  Comment 
The Ebola trade is having a rough day.  Tekmira Pharmaceuticals, which has had a volatile three days, was down 18% on Tuesday after gains of 45% and 15% on Friday and Monday, respectively. Friday's pop in Tekmira followed a Thursday evening...
StreetInsider.com  Aug 11  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/WHO+Updates+on+Ebola+Outbreak+Containment+Efforts+%28TKMR%29+%28BCRX%29+%28SRPT%29/9740228.html for the full story.
StreetInsider.com  Aug 8  Comment 
52-Week High: BioCryst Pharma (Nasdaq: BCRX) $14.58. BioCryst up again Friday following WHO news that Ebola has become an international public health emergency. Shares are up nearly 14 percent on the week. For more color, click here. Air...
Benzinga  Aug 8  Comment 
Analysts at JP Morgan initiated coverage on shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) with a Overweight rating. The target price for BioCryst Pharmaceuticals is set to $20. BioCryst Pharmaceuticals shares have surged 136.70% over the...





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki